Chapter 1 Overview
   1.1 Definition
   1.2 Electroceuticals vs. Digital Therapeutics
   1.3 Scope

Chapter 2 Understanding Electroceuticals Technology
   2.1 Understanding TMS
      2.1.1 Clinical Evidence Development
      2.1.2 Treatment Process of rTMS
      2.1.3 Latest Technology Trends
   2.2 Understanding tDCS
      2.2.1 Clinical Evidence Development
      2.2.2 Treatment Process of tDCS

Chapter 3 Current Market of Electroceuticals
   3.1 Current Market of Korea
      3.1.1 Major Suppliers of Korea
      3.1.2 Electroceuticals and National Health Insurance
      3.1.3 Clinical Trial Approvals of Korea
   3.2 Global Market of Electroceuticals
      3.2.1 Major Suppliers of Global Market
      3.2.2 Clinical Trial Approvals of Global Market
      3.2.3 Electroceuticals R&D of Global Market

Chapter 4 Demand Forecast
   4.1 Electroceuticals by Indication
      4.1.1 Depression
      4.1.2 Anxiety Disorder
      4.1.3 Insomnia
      4.1.4 Obsessive-compulsive disorder
      4.1.5 Addiction
   4.2 Market Size of Pharmaceuticals by Indcation
   4.3 Opportunites and Restraints
      4.3.1 Market Opportunities
      4.3.2 Market Restraints

Chapter 5 Business Strategy Suggestions
   5.1 Korean Market Access Strategy
   5.2 Global Market Access Strategy
   5.3 Conclusion

References

Appendix 1. Itemized Disease Code for Target Market
Appendix 2. Non-Reimbursement TMS Expenses for Individual Institution
Appendix 3. FDA Approval for TMS Devices

[Tabel 1] Key Features of Each Generation
[Tabel 2] Electroceuticals vs. Digital Therapeutics
[Tabel 3] Major Non-Invasive Methods
[Tabel 4] Electroceuticals Marketed and Developed (as of December 2022)
[Tabel 5] Remed Product Approvals
[Tabel 6] Current Businesses of Remed
[Tabel 7] Ybrain Product Approvals
[Tabel 8] Top 5 Non-Reimbursement TMS Expenses
[Tabel 9] Notifications on TMS-Related New Health Technology Suspended
[Tabel 10] Major Clinical Trials on TMS in Korea
[Tabel 11] Major Clinical Trials on tDCS in Korea
[Tabel 12] Global Major Clinical Trials on rTMS
[Tabel 13] Global Major Clinical Trials on tDCS
[Tabel 14] Cochrane and NICE Studies on TMS (Including rTMS)
[Tabel 15] Cochrane and NICE Studies on tDCS
[Tabel 16] Five-Year Forecast of Indications
[Tabel 17] Number of Claims for Depression
[Tabel 18] Five-Year Forecast of Depression Market
[Tabel 19] Number of Claims for Anxiety Disorder
[Tabel 20] Five-Year Forecast of Anxiety Disorder Market
[Tabel 21] Number of Claims for Insomnia
[Tabel 22] Five-Year Forecast of Insomnia Market
[Tabel 23] Number of Claims for Obsessive-Compulsive Disorder
[Tabel 24] Five-Year Forecast of Obsesseive-Compulsive Disorder Market
[Tabel 25] Number of Claims for Addiction
[Tabel 26] Number of Claims for Addiction on Gambling
[Tabel 27] Market Size of Pharmaceuticals by Indcation
[Tabel 28] List of Pharmaceuticals Approved by Indication
[Tabel 29] Types of Documents to be Submitted (Rules on Medical Device Approval, Notification, and Review Article 28)
[Tabel 30] Medical Departments Available for Primary Care
[Tabel 31] FDA Product Codes for TMS

[Fig 1] Types of Electroceuticals
[Fig 2] DLPFC (Dorsolateral Prefrontal Cortex) and VMPFC (Ventromedial Prefrontal Cortex)
[Fig 3] Therapeutic Mechamism of rTMS
[Fig 4] Therapeutic Mechamism of tDCS
[Fig 5] Product Image of ALTMS
[Fig 6] Product Image of MINDSTEAM
[Fig 7] Pathway to Class Ⅱ Approval
[Fig 8] Pathway to Class Ⅲ & Class Ⅳ Approval
[Fig 9] IDE Approval by MFDS
[Fig 10] Exemptions from IDE Approval by MFDS

1 Remed
2 NuEyne
3 Ybrain
4 Neurophet
5 Brainsway
6 Neuronetics
7 Magstim
8 Magventure